10-Q: Rhythm Pharma Reports Strong Q3 Revenue, Advances Pipeline

Rhythm Pharmaceuticals reports significant revenue growth and positive clinical trial results for its lead assets, extending its cash runway for at least 24 months.

Summary

• Product revenue, net, increased by 54% to $51.3 million for the three months ended September 30, 2025, compared to $33.3 million for the same period in 2024.
• For the nine months ended September 30, 2025, total revenues grew by 50% to $132.5 million, up from $88.3 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, decreased by 31% to $149.0 million, compared to $217.3 million for the same period in 2024, primarily due to non-recurring acquired IPR&D costs in 2024.
• The company announced positive topline results from the pivotal Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity, meeting its primary endpoint with statistically significant BMI reduction.
• The U.S. FDA accepted the supplemental New Drug Application (sNDA) for setmelanotide for hypothalamic obesity, granting Priority Review with a PDUFA goal date of December 20, 2025.
• The European Medicines Agency (EMA) confirmed validation of the Type II variation submissions for setmelanotide for hypothalamic obesity, with review commencing on August 16, 2025.
• Bivamelagon, an investigational oral small molecule MC4R agonist, achieved statistically significant and clinically meaningful BMI reductions in a Phase 2 trial for acquired hypothalamic obesity.
• The company closed a public offering on July 11, 2025, raising approximately $188.7 million in net proceeds.
• As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $416.1 million, which management believes is sufficient to fund operations for at least 24 months.

Sentiment

Score: 8

Explanation: The company demonstrates strong commercial growth for its approved product, significant progress in its clinical pipeline with positive Phase 3 and Phase 2 results for new indications, and a strengthened financial position from a recent capital raise, extending its cash runway. While operating losses persist and ex-U.S. revenue saw a temporary dip due to pricing adjustments, the overall trajectory and strategic advancements are highly positive.

Positives

• Product revenue increased by 54% year-over-year for Q3 2025 and 56% for the nine-month period, driven by increased sales volume of IMCIVREE.
• Net loss for the nine months ended September 30, 2025, significantly decreased by 31% compared to the prior year, indicating improved financial efficiency or reduced one-time expenses.
• Positive topline results from the Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity demonstrate clinical efficacy and potential for a new indication.
• FDA granted Priority Review for the sNDA for setmelanotide in hypothalamic obesity, signaling potential for accelerated approval.
• EMA validated the Type II variation submissions for setmelanotide in hypothalamic obesity, advancing regulatory review in Europe.
• Bivamelagon showed statistically significant and clinically meaningful BMI reductions in its Phase 2 trial, indicating promising pipeline expansion.
• A public offering in July 2025 raised $188.7 million in net proceeds, significantly strengthening the company's liquidity and extending its cash runway to at least 24 months.
• IMCIVREE is the first-ever therapy approved or authorized for certain rare MC4R pathway diseases in major global markets.

Negatives

• The company continues to incur significant operating losses, with a net loss of $52.9 million for Q3 2025 and $149.0 million for the nine months ended September 30, 2025.
• Ex-U.S. revenue decreased by 21% sequentially in Q3 2025, primarily due to a $3.2 million reduction related to a French reimbursement pricing agreement, with $1.7 million of this reduction relating to periods prior to 2025.
• The accumulated deficit reached $1.3 billion as of September 30, 2025, reflecting historical operating losses.
• The company terminated its exclusive license agreement with RareStone Group Ltd., resulting in a $5.0 million net reduction in license revenue for the nine months ended September 30, 2025.
• A U.S. government shutdown on October 1, 2025, could significantly impact the FDA's ability to timely review regulatory submissions, potentially delaying approvals.

Risks

• The company has a limited operating history as a commercial-stage biopharmaceutical company and has incurred significant operating losses since inception, with expectations of continued losses for the foreseeable future.
• Future funding is dependent on obtaining capital from third parties, and there is no guarantee that additional equity or other financing will be available on acceptable terms, or at all.
• The Royalty Interest Financing Agreement (RIFA) could restrict the company's ability to commercialize IMCIVREE, limit cash flow, and expose it to risks, including acceleration of payments upon a change of control or event of default.
• Positive results from earlier clinical trials may not be predictive of later clinical trial success, and interim or topline data may change as more patient data become available.
• The exclusive license agreement with LG Chem, Ltd. (LGC) for bivamelagon is important, and failure to adequately perform or termination of the agreement could lead to loss of rights.
• The number of patients with MC4R pathway variants is small and not precisely established, and if actual patient numbers are smaller than estimated, revenue and profitability could be adversely affected.
• Delays or difficulties in patient enrollment and/or retention in clinical trials could delay or prevent regulatory submissions or approvals.
• Research and development in the pharmaceutical industry is costly, risky, time-intensive, and complicated, particularly for early-stage programs like the CHI program.
• Setmelanotide, RM-718, or bivamelagon may cause undesirable side effects that could delay or prevent additional regulatory approvals, limit commercial labeling, or result in negative consequences post-approval.
• The company may not be able to obtain or maintain orphan drug designations or exclusivity, and even with exclusivity, competitors may obtain approval for different drugs treating the same indications.
• Breakthrough Therapy or PRIME designations do not guarantee faster development, regulatory review, or approval.
• The company may not be able to translate current formulations into alternate, commercially successful ones, such as a once-weekly formulation of setmelanotide, and has paused its development in favor of RM-718.
• The requirement for clearance, approval, or certification of an in vitro companion diagnostic device could delay or prevent additional regulatory approvals.
• Reliance on third parties to conduct research, discovery, and clinical trials exposes the company to risks if these parties do not successfully carry out their obligations or meet timelines.
• Successful commercialization depends on obtaining and maintaining coverage and adequate reimbursement from governmental authorities, private health insurers, and other third-party payors.
• The company may not achieve or maintain market acceptance for IMCIVREE, which would limit revenue generation.
• The biotechnology and pharmaceutical industries are intensely competitive, and failure to compete effectively could harm the business.
• Potential product liability exposure could result in substantial liability and harm the business.
• Complete reliance on third-party suppliers for manufacturing clinical and commercial drug supplies introduces risks related to compliance with GMPs and supply chain disruptions.
• Inability to adequately protect proprietary technology or maintain issued patents could allow competitors to erode competitive advantage.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Infringement of intellectual property rights of others could prevent or delay product development or increase commercialization costs.
• Claims challenging the inventorship or ownership of patents and other intellectual property could lead to loss of valuable rights.
• Issued patents could be found invalid or unenforceable if challenged in court.
• The company does not seek to protect intellectual property rights in all jurisdictions, and enforcement may be difficult in some countries.
• Dependence on licensed intellectual property means loss of rights could prevent continued development or commercialization of setmelanotide or bivamelagon.
• Failure to secure trademark registrations in certain foreign jurisdictions could adversely affect the business.
• Failure to obtain an extension of patent protection under Hatch-Waxman Amendments and similar foreign legislation could materially harm the business.
• Changes in U.S. patent law could diminish the value of patents.
• Subject to claims of wrongful use or disclosure of alleged trade secrets by employees.
• The regulatory and marketing approval process is expensive, time-consuming, and uncertain, potentially delaying or preventing commercialization.
• Future regulatory legislation or regulation, such as the EU pharmaceutical legislation review or changes to the UK clinical trials regulations, may increase the difficulty and cost of obtaining marketing approval.
• Disruptions at the FDA, including those caused by government shutdowns, funding shortages, or staffing limitations, could hinder timely review and approval of regulatory submissions.
• Failure to obtain marketing approval in foreign jurisdictions would prevent products from being marketed abroad.
• Terms of current and future marketing approvals and ongoing regulation may limit how products are manufactured and marketed, requiring substantial resources for compliance.
• Current and future healthcare reform legislation or regulation (e.g., ACA, IRA, OBBBA) may increase costs, adversely affect prices, and negatively impact business and results of operations.
• Failure to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs could lead to penalties and sanctions.
• The FDA and other regulatory agencies actively enforce laws and regulations prohibiting the promotion of off-label uses, limiting marketing activities.
• Subject to federal, state, and foreign healthcare laws and regulations, including fraud and abuse laws, health information privacy and security laws, and antitrust laws, with potential for criminal sanctions, damages, and substantial civil penalties for non-compliance.
• Employee misconduct or other improper activities, including violating regulatory standards or engaging in insider trading, could significantly harm the business.
• Actual or perceived failure to comply with data protection, privacy, and security laws and regulations (e.g., GDPR, CCPA) could lead to government enforcement actions and significant penalties.
• Future growth depends on penetrating foreign markets, which involves additional regulatory burdens and risks.
• Laws and regulations governing international operations may preclude development, manufacturing, and selling products outside the U.S. and require costly compliance programs.
• The results of the United Kingdom's departure from the EU (Brexit) and differing regulations may negatively affect the business.
• Future success depends on the ability to retain key employees and consultants and to attract, retain, and motivate qualified personnel.
• The company will need to develop and expand, and may encounter difficulties in managing this development and expansion, which could disrupt operations.
• Information technology systems, or those of third-party contractors, may fail or suffer security breaches, potentially disrupting development programs, leading to regulatory investigations, enforcement actions, and lawsuits.
• Directors and executive officers and their affiliated entities own a significant percentage of stock and can exert significant influence over stockholder approval matters.
• Market volatility may affect the stock price and the value of investment.
• Quarterly operating results may fluctuate significantly.
• Ability to use certain net operating loss carryovers and other tax attributes may be limited.
• Substantial future sales or perceived potential sales of common stock in the public market could cause the price to decline significantly.
• Increased risk of securities litigation, including class action litigation.
• No intention to pay dividends on common stock, so return on investment depends on stock price appreciation.
• Common stock is subordinated to Series A Convertible Preferred Stock.
• Provisions in the certificate of incorporation and bylaws and Delaware law might discourage, delay, or prevent a change in control or changes in management.
• Exclusive forum provisions in corporate documents could limit stockholders' ability to obtain an alternate preferred judicial forum for disputes.
• Acquisitions, strategic alliances, or joint ventures may not realize their intended benefits.
• An active market for common stock may not be maintained.
• If securities or industry analysts do not continue to publish research or publish unfavorable reports, stock price and trading volume could decline.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights.
• Unfavorable global political or economic conditions could adversely affect business, financial condition, or results of operations.
• Business interruptions (e.g., natural disasters, public health crises) could adversely affect operations.
• Substantial costs of operating as a public company, including compliance initiatives and the need to hire additional qualified personnel.
• Failure to maintain an effective system of internal control over financial reporting could prevent accurate financial reporting or fraud prevention.
• Increasing focus on environmental sustainability and social initiatives could increase costs, harm reputation, and adversely impact financial results.
• Short sellers of stock may be manipulative and drive down the market price.

Future Outlook

The company expects continued growth in IMCIVREE sales as it identifies and treats more patients and secures reimbursement in international markets. Research and development expenses are projected to increase significantly as setmelanotide and other product candidates (RM-718, bivamelagon) advance through development. Selling, general, and administrative expenses are also anticipated to rise to support expanding commercialization efforts and global operations. Management believes existing cash resources are sufficient to fund operations for at least 24 months. Key near-term milestones include disclosing preliminary Phase 2 results for setmelanotide in Prader-Willi syndrome in Q4 2025, receiving an FDA decision for setmelanotide in hypothalamic obesity by December 20, 2025, and announcing topline data for the Phase 3 EMANATE trial and Japanese cohort of the HO trial in Q1 2026. The company also plans to initiate a pivotal Phase 3 trial for bivamelagon in acquired hypothalamic obesity in 2026, pending regulatory feedback.

Management Comments

• Management believes that the Company's existing cash resources will be sufficient to fund the Companys operations through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q with the SEC.
• We expect that our cash and cash equivalents and short-term investments as of September 30, 2025, will be sufficient to fund our planned operations for at least 24 months.
• We expect our sales of IMCIVREE will continue to grow as we identify and treat more patients with this disease and obtain reimbursement throughout the international markets in which we operate, however, we cannot estimate or predict with certainty the rates at which sales in any of our markets will grow and whether such sales will grow at a higher or lower pace as compared to sales in the United States.
• We expect cost of sales as a percentage of revenue to continue to be in a range of 10% to 12% in the foreseeable future.
• We expect research and development costs to increase significantly for the foreseeable future as our setmelanotide and other development programs progress.
• We anticipate that our selling, general and administrative expenses will increase in the future to support our continued and expanding commercialization efforts for IMCIVREE in the United States and the European Union as well as increased costs of operating as a global, commercial-stage biopharmaceutical public company.

Industry Context

Rhythm Pharmaceuticals operates in the highly competitive biopharmaceutical industry, specializing in rare neuroendocrine diseases, particularly MC4R pathway diseases. IMCIVREE is positioned as a precision medicine, differentiating it from broader obesity treatments like GLP-1 receptor agonists and GIP/GLP-1 agonists, which do not target the underlying genetic deficiencies. The company is navigating evolving regulatory landscapes in the EU and UK, with new clinical trial regulations and HTA frameworks. U.S. healthcare reform, including the Inflation Reduction Act and the One Big Beautiful Bill Act, is impacting drug pricing and reimbursement, potentially increasing discounts and reducing Medicaid funding. The industry is also seeing an increasing focus on AI technologies, which presents both opportunities and regulatory challenges.

Comparison to Industry Standards

• IMCIVREE is highlighted as the 'first-ever therapy developed for patients with certain rare diseases' approved or authorized in the U.S., EU, UK, and Canada, indicating a pioneering role in its specific niche of MC4R pathway diseases.
• The company differentiates its MC4R agonists from general obesity treatments, such as glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists, by emphasizing that IMCIVREE specifically restores function impaired by genetic deficiencies in the MC4R pathway, which is the root cause of hyperphagia and obesity in its target patient population.

Corporate Governance

Legal Proceedings

• The company is not presently subject to any pending or threatened litigation that it believes, if determined adversely, would reasonably be expected to have a material adverse effect on its business or financial results.

Related Party Transactions

• Expenses paid directly to related parties for the three and nine months ended September 30, 2025 and 2024, were immaterial.
• Outstanding payments due to related parties as of September 30, 2025 and December 31, 2024 were immaterial.

Stakeholder Impact

• Shareholders: Experience dilution from recent equity offerings but benefit from strengthened liquidity and potential for stock price appreciation due to positive clinical developments and commercial growth. Common stock is subordinated to Series A Convertible Preferred Stock.
• Patients: Benefit from the continued development and commercialization of IMCIVREE for rare neuroendocrine diseases, with new indications like hypothalamic obesity potentially offering the first approved therapy. New drug candidates (RM-718, bivamelagon) offer future therapeutic options.
• Employees: The company's expansion in R&D and commercial operations leads to increased hiring, but also presents challenges in recruitment and retention.
• Third-party Payors: Ongoing negotiations for reimbursement and the impact of healthcare reform legislation (e.g., IRA, OBBBA) will influence coverage and pricing for IMCIVREE.
• Suppliers/CMOs: Continued reliance on third-party manufacturers for drug supply, requiring robust oversight and compliance with GMPs.

Next Steps

• Disclose preliminary results from the Phase 2 trial evaluating setmelanotide in Prader-Willi syndrome in Q4 2025.
• Receive a decision from the FDA on the sNDA for setmelanotide in conditions associated with acquired hypothalamic obesity by the PDUFA goal date of December 20, 2025.
• Complete enrollment in the Phase 1, Part C trial evaluating the weekly MC4R agonist RM-718 in patients with acquired hypothalamic obesity in Q1 2026.
• Announce topline data in the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired hypothalamic obesity in Q1 2026.
• Announce topline data in the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in Q1 2026.
• Complete enrollment in the setmelanotide Phase 3 trial substudy in congenital hypothalamic obesity in H1 2026.
• Pending further feedback from U.S. and European regulatory agencies, initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired hypothalamic obesity in 2026.

Key Dates

Recommendation

Rhythm Pharmaceuticals demonstrates strong commercial momentum with IMCIVREE, evidenced by significant revenue growth. The positive Phase 3 results for setmelanotide in hypothalamic obesity, coupled with FDA Priority Review and EMA validation, de-risk a major pipeline expansion. The promising Phase 2 data for bivamelagon further strengthens the long-term pipeline. A substantial capital raise has significantly extended the company's financial runway, providing stability for ongoing R&D and commercialization efforts. While the company remains unprofitable and faces inherent biotech risks, the clear clinical progress in addressing unmet medical needs in rare diseases, combined with a solid financial position, presents a compelling long-term investment opportunity for growth-oriented investors.

Keywords

Rhythm Pharmaceuticals, RYTM, IMCIVREE, setmelanotide, hypothalamic obesity, Bardet-Biedl syndrome, BBS, POMC deficiency, LEPR deficiency, MC4R pathway, biopharmaceutical, rare diseases, obesity, hyperphagia, clinical trials, Phase 3 TRANSCEND, sNDA, FDA Priority Review, EMA validation, bivamelagon, RM-718, drug development, Q3 2025 earnings, financial results, capital raise, biotech, orphan drug, precision medicine